Pharmaceutical

Ascidian launches first-ever clinical study of RNA exon editor for vision loss

An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.

Jan 29, 2024 - 18:00
Ascidian launches first-ever clinical study of RNA exon editor for vision loss
An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.
Read the original article

Tags:

Previous Article

King Charles’ diagnosis raises awareness on prostate condition 

Next Article

Moderna leads the development of mRNA vaccines in infectious diseases

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Carmell to merge with regenerative medicine company Axolotl

Carmell to merge with regenerative medicine company Axo...

Jul 29, 2023

Another recall: does Philips have a quality control problem?

Another recall: does Philips have a quality control pro...

Feb 10, 2024

Mental illness, drug addiction go hand in glove, Biden’s drug czar tells lawmakers

Mental illness, drug addiction go hand in glove, Biden’...

Jul 28, 2023